English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
Add to Basket
  Local TagsRelease HistoryDetailsSummary

Released
Patent

Total synthesis and immunological evaluation of saccharide moieties of the lipopolysaccharide from neisseria meningitidis

MPS-Authors
/persons/resource/persons121849

Seeberger,  Peter H.
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons122050

Yang,  You
Peter H. Seeberger - Automated Systems, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons121100

Chakkumkal,  Anish
Chakkumal Anish, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons121765

Reinhardt,  Anika
Chakkumal Anish, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)

2364340.pdf
(Publisher version), 8MB

Supplementary Material (public)
There is no public supplementary material available
Citation

Seeberger, P. H., Yang, Y., Chakkumkal, A., & Reinhardt, A.(2014). Total synthesis and immunological evaluation of saccharide moieties of the lipopolysaccharide from neisseria meningitidis.


Cite as: https://hdl.handle.net/11858/00-001M-0000-002C-03F3-0
Abstract
The present invention relates to the total chemical synthesis of the monosaccharide 35# (R'-H), the disaccharide 36# (R'<>H; R''-H), the trisaccharide 37# (R'<>H; R''<>H; R'''<>H) and the tetrasaccharide 1# (R'<>H; R''<>H; R'''<>H) of the following general formula wherein R represents -Y-NH2Y represents a linker R' is H or R'' is H or R''' is H or of the lipopolysaccharide from Neisseria meningitidis, as well as to the trisaccharide 37# and the tetrasaccharide 1#, to vaccines containing at least one of the saccharides 1#, 35#, 36#, and 37# and to the use of such vaccine for immunization against diseases caused by infection with bacteria containing the tetrasaccharide [alpha]-GlcNAc-(1->2)-[alpha]-Hep-(1->3)-[alpha]-Hep-(1->5)-[alpha]-Kdo or the trisaccharide [alpha]-Hep-(1->3)-[alpha]-Hep-(1->5)-[alpha]-Kdo or [alpha]-GlcNAc-(1->2)-[alpha]-Hep-(1->3)-[alpha]-Hep, especially for immunization against meningitis, septicaemia, pneumonia and nasopharyngitis caused by Neisseria meningitidis.